The Impact of US-China Decoupling on Drug Supply Chain for Pharmaceutical Companies
Saturday, 23 March 2024, 13:00
US-China Decoupling
A recently proposed bill in Congress aims to target Chinese biotech businesses, posing supply chain risks for pharmaceutical companies.
Supply Chain Vulnerabilities
- Complex Dependencies: Drug companies rely on Chinese biotech firms for various stages of drug development.
- Disruption Potential: Decoupling may disrupt established sourcing strategies, affecting the availability of crucial components.
- Risk Mitigation Required: Pharma companies need to assess vulnerabilities and enhance supply chain resilience.
This development underscores the need for companies to address vulnerabilities and diversify sourcing strategies to mitigate risks.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.